Ex-FDA chief Crawford moves into private-sector lobbying role:
This article was originally published in Clinica
Executive Summary
Former FDA commissioner Dr Lester Crawford has joined the Washington DC-based lobbying firm Policy Directions as senior counsel. Dr Crawford mysteriously resigned from his post in September only three months after Senate confirmation. He was embroiled in a controversy over whether he had politicised the agency for overruling staff and outside advisors by indefinitely postponing a decision on whether to grant Barr Laboratories' emergency contraceptive Plan B product OTC status. His sudden departure is still under investigation by the Health and Human Services department's inspector general. Policy Directions represents several food, drug and device clients, including Bausch & Lomb, Baxter Healthcare, Bayer Diagnostics, Genzyme, and Visx. To read more about lobbying, see www.healthcarelobbyist.com.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.